SAVELLA: source applicability and renal evidence limits
Use the intact renal-dosing section, not the malformed moderate-renal PK range in the mirror. Reduced maintenance and initial titration are separate instructions.
Before applying: Do not skip titration or abruptly stop extended treatment.
Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Rxlist source
SAVELLA: selected RX renal passage
Product / population
Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.
Renal measure
Estimated CrCl, mL/min; severe 5-29
Source revision
Revision date not established in reviewed mirror passage.
Retrieved
2026-11-07 (not the revision date)
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
ESRD: not recommended. Mild: no adjustment; moderate: caution.
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
Section 2.2; discontinuation context
The intact renal dosing section reports reduced maintenance at CrCl 5-29, a response-dependent increase, and ESRD avoidance. A malformed moderate-renal range in the PK paragraph was excluded from numerical interpretation.
Source revision: Revision date not established in reviewed mirror passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
SAVELLA: selected primary-label renal guidance and limits
Source retrieved 2026-11-07 - confirm current applicability
No dialysis regimen established in selected content
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
SAVELLA: source applicability and renal evidence limits
Use the intact renal-dosing section, not the malformed moderate-renal PK range in the mirror. Reduced maintenance and initial titration are separate instructions.
How to use this: Do not skip titration or abruptly stop extended treatment.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
SAVELLA: selected primary-label renal guidance and limits
Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/milnacipran/
Usual Dosing (Adults)
Fibromyalgia; the source states not approved for pediatric use. Take orally with or without food; food may improve tolerability. Day 1: 12.5 mg once. Days 2-3: 12.5 mg twice daily. Days 4-7: 25 mg twice daily. After day 7: 50 mg twice daily (recommended 100 mg/day). Depending on response, increase to 100 mg twice daily; doses above 200 mg/day were not studied. Taper rather than abruptly stopping after extended treatment.
Mild impairment: no adjustment. Moderate impairment: caution. Severe impairment, estimated CrCl 5-29 mL/min: reduce maintenance by 50% to 25 mg twice daily; may increase to 50 mg twice daily according to response.
DailyMed / product prescribing information · Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.
Renal method: Estimated CrCl, mL/min; severe 5-29 Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
ESRD: not recommended. Mild: no adjustment; moderate: caution.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 2.2; discontinuation context
Mild impairment requires no adjustment; use caution in moderate impairment. At CrCl 5-29 mL/min, reduce maintenance to 25 mg twice daily; depending on response it may increase to 50 mg twice daily. ESRD use is not recommended. This is maintenance guidance, not an instruction to skip initial titration. Monitor tolerability and taper after extended use.
GlobalRPh RX List / label mirror · Adult oral SAVELLA for fibromyalgia; not levomilnacipran extended-release.
Renal method: Estimated CrCl, mL/min; severe 5-29 Source date: Revision date not established in reviewed mirror passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
ESRD: not recommended. Mild: no adjustment; moderate: caution.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 2.2; discontinuation context
The intact renal dosing section reports reduced maintenance at CrCl 5-29, a response-dependent increase, and ESRD avoidance. A malformed moderate-renal range in the PK paragraph was excluded from numerical interpretation.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
